Who
Jeffrey T. L. Smith
EVP & Chief Medical Officer
Company insider
Files Form 4 as: EVP & Chief Medical Officer, Zymeworks; Managing Director, Alder Biopharmaceuticals.
In numbers
- Trades disclosed
- 155
- Buys
- 0
- Sells
- 35
- Bought
- $0
- Sold
- $8.0M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 7 May 2014
- Last trade
- 12 Jan 2026
- Last filed
- 12 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jan 2026filed 12 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code M | —17,666 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Sold | $211K9,310 at $22.67 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,666 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,666 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code M | —17,666 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Sold | $211K9,310 at $22.67 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Sold | $264K10,538 at $25.10 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 5 Jan 2026filed 5 Jan 2026 | ZYME ZymeworksBiotechnology | SEC FORM 4 Sold | $265K10,538 at $25.10 | filing |
| 10 Jan 2025filed 10 Jan 2025 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —79,000 at $0.00 | filing |
| 10 Jan 2025filed 10 Jan 2025 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,000 at $0.00 | filing |
| 6 Jan 2025filed 6 Jan 2025 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 6 Jan 2025filed 6 Jan 2025 | ZYME ZymeworksBiotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 6 Jan 2025filed 6 Jan 2025 | ZYME ZymeworksBiotechnology | SEC FORM 4 Sold | $166K11,110 at $14.92 | filing |
| 5 Jan 2024filed 8 Jan 2024 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 5 Jan 2024filed 8 Jan 2024 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —17,271 at $0.00 | filing |
News
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3ZYME · saultstar.com · 23 Oct 2026Zymeworks Names Suzanne Monahan to Lead YUPELRI Commercial StrategyZYME · econotimes.com · 19 Oct 2026Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance BiopharmaZYME · manilatimes.net · 19 Oct 2026
0 headlines in the last 90 days name Jeffrey T. L. Smith; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.